{"id":"NCT03074331","sponsor":"Gilead Sciences","briefTitle":"Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","officialTitle":"A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-23","primaryCompletion":"2018-02-07","completion":"2018-02-07","firstPosted":"2017-03-08","resultsPosted":"2019-03-19","lastUpdate":"2019-03-19"},"enrollment":130,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["EpclusaÂ®","GS-7977/GS-5816"]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL 12 Weeks","deltaMin":93,"sd":null}],"pValues":[{"comp":"OG000","p":"0.009"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":7},"locations":{"siteCount":16,"countries":["India"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":129},"commonTop":[]}}